Intracisternal delivery of AAV9 results in oligodendrocyte and motor neuron transduction in the whole central nervous system of cats

Gene Therapy

Volumn 21, Issue 5, 2014, Pages 522-528

  Bucher, T ^a   Dubreil, L ^b   Colle, M A ^c   Maquigneau, M ^a   Deniaud, J ^b   Ledevin, M ^c   Moullier, P ^d   Joussemet, B ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b INRA UMR 703   (France)

^c LUNAM UNIVERSITÉ   (France)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CENTRAL NERVOUS SYSTEM; CERVICAL SPINAL CORD; CISTERNA MAGNA; CONTROLLED STUDY; EXPERIMENTAL CAT; GENE EXPRESSION; GLIA CELL; GROUPS BY AGE; LUMBAR SPINAL CORD; MOTONEURON; NEWBORN; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; SPINAL CORD NERVE CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL TROPISM; WHITE MATTER; AGE; ANIMAL; BRAIN; CAT; CEREBROSPINAL FLUID; CYTOLOGY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; GLIA; NERVE CELL; SPINAL CORD; VIROLOGY;

AGE FACTORS; ANIMALS; BRAIN; CATS; CEREBROSPINAL FLUID; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; MOTOR NEURONS; NEUROGLIA; NEURONS; OLIGODENDROGLIA; SPINAL CORD; TRANSDUCTION, GENETIC;

EID: 84900032549     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.16     Document Type: Article

References (40)

1. Hester ME, Foust KD, Kaspar RW, Kaspar BK. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr Gene Ther 2009; 9: 428-433
2. Cearley CN, Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006; 13: 528-537
3. Sondhi D, Hackett NR, Peterson DA, Stratton J, Baad M, Travis KM et al. Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. Mol Ther 2007; 15: 481-491
4. Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L et al. Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther 2007; 18: 195-206
5. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 2011; 10: 253-263
6. Prineas JW, Parratt JD. Oligodendrocytes and the early multiple sclerosis lesion. Ann Neurol 2012; 72: 18-31
7. Mekhail M, Almazan G, Tabrizian M. Oligodendrocyte-protection and remyelination post-spinal cord injuries: a review. Prog Neurobiol 2012; 96: 322-339
8. Biffi A, Aubourg P, Cartier N. Gene therapy for leukodystrophies. Hum Mol Genet 2011; 20: R42-R53
9. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009; 27: 59-65
10. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17: 1187-1196
11. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010; 28: 271-274
12. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010; 2: 35ra42
13. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011; 20: 681-693
14. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011; 19: 1058-1069
15. Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011; 19: 1971-1980
16. Gray SJ, Foti SB, Schwartz JW, Bachaboina L, Taylor-Blake B, Coleman J et al. Optimizing promoters for recombinant adeno-associated virus-Mediated gene expression in the peripheral and central nervous system using selfcomplementary vectors. Hum Gene Ther 2011; 22: 1143-1153
17. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust K, Bringas J et al. AAV9 transduction in the central nervous system of non-human primates. Hum Gene Ther 2011; 23: 382-389
18. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Bringas J, Forsayeth J et al. Strong cortical and spinal cord transduction after AAV7 and AAV9 Delivery into the CSF of non-human primates. Hum Gene Ther 2013; 24: 526-532
19. Snyder BR, Gray SJ, Quach ET, Huang JW, Leung CH, Samulski RJ et al. Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther 2011; 22: 1129-1135
20. Federici T, Taub JS, Baum GR, Gray SJ, Grieger JC, Matthews KA et al. Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene Therapy 2011; 19: 852-859
21. Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest 2013
22. Bradbury AM, Cochran JN, McCurdy VJ, Johnson AK, Brunson BL, Gray-Edwards H et al. Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy. Mol Ther 2013; 21: 1306-1315
23. Bagel JH, Sikora TU, Prociuk M, Pesayco JP, Mizisin AP, Shelton GD et al. Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of niemann-pick disease type C. J Neuropathol Exp Neurol 2013; 72: 256-262
24. Mathiason CK, Nalls AV, Seelig DM, Kraft SL, Carnes K, Anderson KR et al. Susceptibility of domestic cats to chronic wasting disease. J Virol 2013; 87: 1947-1956
25. Uddin MM, Hossain MA, Rahman MM, Chowdhury MA, Tanimoto T, Yabuki A et al. Identification of Bangladeshi domestic cats with GM1 gangliosidosis caused by the c.1448GC mutation of the feline GLB1 gene: case study. J Vet Med Sci 2013; 75: 395-397
26. Furusawa Y, Mizukami K, Yabuki A, Kuwamura M, Chang HS, Hossain MA et al. Mutational analysis of the feline CLN3 gene and an ultrastructural evaluation of lysosomal storage materials in a cat with neuronal ceroid lipofuscinosis: an investigation into the molecular basis of the disease. Vet J 2012; 194: 425-428
27. Fyfe JC, Menotti-Raymond M, David VA, Brichta L, Schaffer AA, Agarwala R et al. An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival. Genome Res 2006; 16: 1084-1090
28. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Therapy 2013; 20: 465
29. Bucher T, Colle M, Wakeling E, Dubreil L, Fyfe J, Briot-Nivard D et al. scAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum Gene Ther 2013; 24: 670-682
30. Bell CL, Gurda BL, Van Vliet K, Agbandje-McKenna M, Wilson JM. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J Virol 2012; 86: 7326-7333
31. Shen S, Bryant KD, Sun J, Brown SM, Troupes A, Pulicherla N et al. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol 2012; 86: 10408-10417
32. Bell CL, Vandenberghe LH, Bell P, Limberis MP, Gao GP, Van Vliet K et al. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 2011; 121: 2427-2435
33. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 2011; 286: 13532-13540
34. Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Therapy 2010; 17: 503-510
35. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 2008; 16: 89-96
36. Chen H, McCarty DM, Bruce AT, Suzuki K. Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J Neurosci Res 1999; 55: 504-513
37. Piguet F, Sondhi D, Piraud M, Fouquet F, Hackett NR, Ahouansou O et al. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther 2012; 23: 903-914
38. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, Jude Samulski R. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Therapy 2013; 20: 450-459
39. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801
40. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199: 381-390.